Incyte Corp (NAS:INCY)
$ 57.05 -0.55 (-0.95%) Market Cap: 12.83 Bil Enterprise Value: 9.14 Bil PE Ratio: 17.29 PB Ratio: 2.38 GF Score: 88/100

Incyte Corp Key Studies Within Its Inflammation And Autoimmunity portfolio Corporate Call Transcript

Jun 17, 2019 / 12:00PM GMT
Release Date Price: $81.84 (+5.31%)
Operator

Greetings, and welcome to the Ruxolitinib Cream Phase II Data and Vitiligo Webinar and Conference Call. (Operator Instructions) As a reminder, this conference is being recorded.

It is now my pleasure to introduce your host Mike Booth, Head of Investor Relations. Please go ahead, Mike.

Michael Booth
Incyte Corporation - VP of IR

Thank you, Kevin. Good morning, and welcome to our conference call and webcast to discuss vitiligo, the disease, the medical need and the biological rationale for JAK inhibition as a potential therapy. We will also provide some highlights from the presentation of the Phase II data for ruxolitinib cream as a treatment for patients with vitiligo that were presented at the World Congress of Dermatology over the weekend.

The slides used today in today's webcast are available for download on the Investor section of incyte.com as are the full data slides as presented in Milan on Saturday.

I am joined on the call today, not only by Hervé and by Jim Lee, our Head of Inflammation and Autoimmunity Development, but we

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot